Oncolys BioPharma Secures Japan Approval for Telomelysin in Esophageal Cancer
TOKYO, Japan, June 8, 2026 Oncolys BioPharma has achieved a major milestone in cancer treatment innovation with the Japanese...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TOKYO, Japan, June 8, 2026 Oncolys BioPharma has achieved a major milestone in cancer treatment innovation with the Japanese...
WASHINGTON, D.C., United States, June 9, 2026 The U.S. Food and Drug Administration (FDA) has approved the addition of...
